NRx Pharmaceuticals (NRXP) Q1 2025 earnings summary

Executive summary

• Advanced regulatory filings for NRx-100 and NRx-101, with NDA submissions initiated and accelerated approval sought, targeting FDA PDUFA decisions in 2025.

• Expanded HOPE Therapeutics clinic network through acquisitions and agreements, aiming for significant revenue growth and national presence.

• Leadership restructuring and capital formation positioned the company for a transition to a revenue-generating model.

• Substantially reduced core corporate expenses and ended the quarter with increased cash on the balance sheet.

• Secured over $10 million in non-dilutive financing and additional convertible debt and equity offerings to fund clinic acquisitions and growth.

Financial highlights

• Reported net loss of $5.5 million for Q1 2025, improved from $6.5 million in Q1 2024, with lower R&D ($0.8 million) and G&A ($2.9 million) expenses.

• Loss from operations was $3.8 million, down from $6.0 million year-over-year.

• Cash and cash equivalents totaled $5.5 million as of March 31, 2025, up from $1.4 million at year-end 2024.

• No revenue was generated in Q1 2025 or the prior year.

• Operational efficiencies implemented to extend cash runway and support operations through at least end of 2025.

Outlook and guidance

• Anticipates FDA PDUFA dates for both NRx-100 and NRx-101 in 2025, with NDA filings planned for Q2 2025.

• Sufficient cash and financing expected to support operations and FDA submissions through at least end of 2025.

• Forecasts profitability on a run-rate basis by end of 2025, driven by HOPE Therapeutics revenue and potential drug sales.

• Plans to spin out HOPE Therapeutics and list it on a national stock exchange.

• International expansion for NRx-100 and HOPE Therapeutics under consideration, with interest from global partners.